Selective LMP7 inhibition has been suggested as a therapeutic modality in autoimmune diseases, such as rheumatoid arthritis, since it induces an anti‐inflammatory response at lower doses than nonselective inhibitors, such as bortezomib, and reduces serum autoantibody levels, blocking disease progression.47 The gene discussed is PSMB8; the disease is rheumatoid arthritis.